Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A S Coates

Showing results (121-130 of 150) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VIIA Wallgren, M Bonetti, R D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2008
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?M M Regan, O Pagani, B Walley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2015
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trialE Munzone, A Giobbie-Hurder, B A Gusterson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2006
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)B C Pestalozzi, D Zahrieh, K N Price, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2007
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trialsA Keshaviah, S Dellapasqua, N Rotmensz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2001
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancerM Colleoni, S Gelber, A S Coates, et al.
British Journal of Cancer|November 29, 2007
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancerJ Bernhard, D Zahrieh, J J Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2011
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IXS Aebi, Z Sun, D Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2011
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancerP Karlsson, Z Sun, D Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2009
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trialM Rabaglio, Z Sun, K N Price, et al.
Pageof 15

Showing results (121-130 of 150) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VIIA Wallgren, M Bonetti, R D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2008
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?M M Regan, O Pagani, B Walley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2015
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trialE Munzone, A Giobbie-Hurder, B A Gusterson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2006
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)B C Pestalozzi, D Zahrieh, K N Price, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2007
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trialsA Keshaviah, S Dellapasqua, N Rotmensz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2001
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancerM Colleoni, S Gelber, A S Coates, et al.
British Journal of Cancer|November 29, 2007
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancerJ Bernhard, D Zahrieh, J J Zhang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2011
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IXS Aebi, Z Sun, D Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2011
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancerP Karlsson, Z Sun, D Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2009
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trialM Rabaglio, Z Sun, K N Price, et al.
Pageof 15